Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.29
ILMN's Cash to Debt is ranked higher than
67% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. ILMN: 1.29 )
ILMN' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: 1.29

Equity to Asset 0.52
ILMN's Equity to Asset is ranked higher than
62% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. ILMN: 0.52 )
ILMN' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.94
Current: 0.52

0.36
0.94
Interest Coverage 3.38
ILMN's Interest Coverage is ranked higher than
52% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. ILMN: 3.38 )
ILMN' s 10-Year Interest Coverage Range
Min: 3.38   Max: 9999.99
Current: 3.38

3.38
9999.99
F-Score: 6
Z-Score: 10.19
M-Score: -2.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.44
ILMN's Operating margin (%) is ranked higher than
74% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. ILMN: 9.44 )
ILMN' s 10-Year Operating margin (%) Range
Min: -1775.02   Max: 23.45
Current: 9.44

-1775.02
23.45
Net-margin (%) 8.82
ILMN's Net-margin (%) is ranked higher than
77% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. ILMN: 8.82 )
ILMN' s 10-Year Net-margin (%) Range
Min: -1421.39   Max: 21.65
Current: 8.82

-1421.39
21.65
ROE (%) 8.17
ILMN's ROE (%) is ranked higher than
75% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. ILMN: 8.17 )
ILMN' s 10-Year ROE (%) Range
Min: -67.62   Max: 16.16
Current: 8.17

-67.62
16.16
ROA (%) 4.15
ILMN's ROA (%) is ranked higher than
74% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. ILMN: 4.15 )
ILMN' s 10-Year ROA (%) Range
Min: -33.08   Max: 13.3
Current: 4.15

-33.08
13.3
ROC (Joel Greenblatt) (%) 37.06
ILMN's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. ILMN: 37.06 )
ILMN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2033.68   Max: 78.08
Current: 37.06

-2033.68
78.08
Revenue Growth (%) 17.30
ILMN's Revenue Growth (%) is ranked higher than
92% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ILMN: 17.30 )
ILMN' s 10-Year Revenue Growth (%) Range
Min: -2   Max: 160.9
Current: 17.3

-2
160.9
EBITDA Growth (%) 6.40
ILMN's EBITDA Growth (%) is ranked higher than
73% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. ILMN: 6.40 )
ILMN' s 10-Year EBITDA Growth (%) Range
Min: -70.3   Max: 529.1
Current: 6.4

-70.3
529.1
EPS Growth (%) 1.10
ILMN's EPS Growth (%) is ranked higher than
69% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. ILMN: 1.10 )
ILMN' s 10-Year EPS Growth (%) Range
Min: -40.2   Max: 205.7
Current: 1.1

-40.2
205.7
» ILMN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ILMN Guru Trades in Q2 2013

Paul Tudor Jones 3,100 sh (New)
Pioneer Investments 94,000 sh (+103.02%)
Ron Baron 2,164,898 sh (+77.99%)
Jean-Marie Eveillard 400 sh (unchged)
Vanguard Health Care Fund 2,240,200 sh (unchged)
Louis Moore Bacon Sold Out
John Hussman Sold Out
Andreas Halvorsen Sold Out
Steven Cohen Sold Out
PRIMECAP Management 2,028,200 sh (-2.31%)
Mario Gabelli 24,500 sh (-25.08%)
George Soros 25,000 sh (-37.5%)
» More
Q3 2013

ILMN Guru Trades in Q3 2013

Jim Simons 164,718 sh (New)
Steven Cohen 3,050 sh (New)
Stanley Druckenmiller 506,700 sh (New)
Ron Baron 2,216,345 sh (+2.38%)
PRIMECAP Management 2,035,663 sh (+0.37%)
Vanguard Health Care Fund 2,240,200 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
Paul Tudor Jones 3,100 sh (unchged)
Pioneer Investments 86,127 sh (-8.38%)
Mario Gabelli 18,500 sh (-24.49%)
George Soros 10,102 sh (-59.59%)
» More
Q4 2013

ILMN Guru Trades in Q4 2013

Andreas Halvorsen 1,696,962 sh (New)
PRIMECAP Management 2,048,063 sh (+0.61%)
Vanguard Health Care Fund 2,240,200 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
George Soros 10,102 sh (unchged)
Stanley Druckenmiller 506,700 sh (unchged)
Paul Tudor Jones 3,100 sh (unchged)
Steven Cohen Sold Out
Ron Baron 2,209,790 sh (-0.3%)
Mario Gabelli 16,500 sh (-10.81%)
Pioneer Investments 61,619 sh (-28.46%)
Jim Simons 44,618 sh (-72.91%)
» More
Q1 2014

ILMN Guru Trades in Q1 2014

Steven Cohen 76,780 sh (New)
RS Investment Management 9,315 sh (New)
Jim Simons 365,118 sh (+718.32%)
Andreas Halvorsen 8,866,245 sh (+422.48%)
George Soros 50,102 sh (+395.96%)
PRIMECAP Management 2,262,270 sh (+10.46%)
Paul Tudor Jones 3,188 sh (+2.84%)
Jean-Marie Eveillard 400 sh (unchged)
Vanguard Health Care Fund 2,160,500 sh (-3.56%)
Ron Baron 1,705,740 sh (-22.81%)
Mario Gabelli 10,400 sh (-36.97%)
Stanley Druckenmiller 253,300 sh (-50.01%)
Pioneer Investments 30,351 sh (-50.74%)
» More
» Details

Insider Trades

Latest Guru Trades with ILMN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 Reduce -22.81%0.23%$108.61 - $179.54 $ 175.8917%1705740
George Soros 2014-03-31 Add 395.96%0.06%$108.61 - $179.54 $ 175.8917%50102
Mario Gabelli 2014-03-31 Reduce -36.97%$108.61 - $179.54 $ 175.8917%10400
George Soros 2013-09-30 Reduce -59.59%0.01%$73.36 - $85.34 $ 175.89124%10102
Mario Gabelli 2013-09-30 Reduce -24.49%$73.36 - $85.34 $ 175.89124%18500
John Hussman 2013-06-30 Sold Out 0.79%$54.24 - $74.95 $ 175.89167%0
Ron Baron 2013-06-30 Add 77.99%0.37%$54.24 - $74.95 $ 175.89167%2164898
George Soros 2013-06-30 Reduce -37.5%0.01%$54.24 - $74.95 $ 175.89167%25000
Mario Gabelli 2013-06-30 Reduce -25.08%$54.24 - $74.95 $ 175.89167%24500
Daniel Loeb 2013-03-31 Sold Out 1.5%$48.36 - $55.59 $ 175.89240%0
John Hussman 2013-03-31 Reduce -60%0.9%$48.36 - $55.59 $ 175.89240%400000
Vanguard Health Care Fund 2013-03-31 New Buy0.48%$48.36 - $55.59 $ 175.89240%2240200
George Soros 2013-03-31 New Buy0.03%$48.36 - $55.59 $ 175.89240%40000
John Burbank 2013-03-31 Sold Out 0.01%$48.36 - $55.59 $ 175.89240%0
Daniel Loeb 2012-12-31 New Buy1.5%$45.19 - $56.39 $ 175.89247%1500000
John Hussman 2012-12-31 Add 57.73%0.55%$45.19 - $56.39 $ 175.89247%1000000
John Burbank 2012-12-31 New Buy0.21%$45.19 - $56.39 $ 175.89247%100000
PRIMECAP Management 2012-12-31 Add 60.44%0.07%$45.19 - $56.39 $ 175.89247%2076200
Joel Greenblatt 2012-12-31 Sold Out 0.03%$45.19 - $56.39 $ 175.89247%0
Ron Baron 2012-09-30 Add 130.47%0.22%$39.41 - $48.48 $ 175.89309%1242007
John Hussman 2012-09-30 Reduce -21.73%0.13%$39.41 - $48.48 $ 175.89309%634000
John Burbank 2012-06-30 Sold Out 0.14%$38.03 - $52.7 $ 175.89299%0
Ron Baron 2012-06-30 Add 1970.73%0.13%$38.03 - $52.7 $ 175.89299%538908
George Soros 2012-06-30 Sold Out 0.1%$38.03 - $52.7 $ 175.89299%0
Joel Greenblatt 2012-06-30 Reduce -32.49%0.03%$38.03 - $52.7 $ 175.89299%11850
Mario Gabelli 2012-06-30 Add 239.39%0.01%$38.03 - $52.7 $ 175.89299%33600
John Griffin 2012-03-31 Sold Out 0.5%$31.43 - $55.15 $ 175.89293%0
John Burbank 2012-03-31 New Buy0.14%$31.43 - $55.15 $ 175.89293%80000
George Soros 2012-03-31 New Buy0.1%$31.43 - $55.15 $ 175.89293%125102
Joel Greenblatt 2012-03-31 Reduce -46.96%0.06%$31.43 - $55.15 $ 175.89293%17554
Mario Gabelli 2012-03-31 New Buy$31.43 - $55.15 $ 175.89293%9900
Joel Greenblatt 2011-12-31 Add 453.69%0.1%$26.04 - $40.01 $ 175.89493%33094
Ron Baron 2011-12-31 New Buy0.01%$26.04 - $40.01 $ 175.89493%26025
John Griffin 2011-09-30 New Buy0.72%$41.32 - $77.88 $ 175.89210%865000
Joel Greenblatt 2011-09-30 New Buy0.04%$41.32 - $77.88 $ 175.89210%5977
Ron Baron 2011-09-30 Sold Out 0.0237%$41.32 - $77.88 $ 175.89210%0
John Hussman 2011-06-30 Reduce -33.33%0.58%$66.62 - $76.26 $ 175.89146%1000000
Ron Baron 2011-06-30 Reduce -33.81%0.01%$66.62 - $76.26 $ 175.89146%56859
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Illumina Inc

Baron Funds Comments on Illumina Inc. - May 29, 2014

Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose 34% in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating.





From Baron Funds' first quarter 2014 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 21, 2014

Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman)





From Baron Funds' first quarter 2014 letter to shareholders.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 12, 2014

Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman)



From Baron Funds' first quarter 2014 letter to shareholders.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 02, 2014

Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the quarter, driven by better-than-expected fourth quarter results, strong 2014 financial guidance, and the announcement of multiple new product introductions. The company's most exciting new product is an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe these developments support our view that Illumina has meaningfully distanced itself from its competitors. We believe that nearly all new orders in the sequencing industry are being won by Illumina, affording the company a de facto monopoly in DNA sequencing devices. Further, Illumina retains this remarkable competitive position at a time when demand for next generation DNA sequencing is accelerating rapidly.



From Baron Funds' first quarter 2014 commentary.





Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Aug 08, 2013

Shares of Illumina, Inc. (ILMN) outperformed during the second quarter. Illumina is the leading provider of next generation DNA sequencing instruments and consumables. In April, the company reported strong first quarter results. Revenues increased 21%, ahead of Wall Street estimates, driven by strength across the entire product portfolio. Earnings also exceeded expectations. We think Illumina's strong first quarter results were driven in part by market share gains, which may have accelerated after the company's main competitor announced it was evaluating strategic alternatives. (Neal Kaufman)

From Ron Baron’s second quarter 2013 commentary.


Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Aug 02, 2013

Illumina, Inc. (ILMN) is the leading manufacturer of instruments and consumables used by scientists engaged in researching applications for 'next generation' DNA sequencing. Illumina's products have been at the forefront of huge recent advances in technology that have brought the cost of sequencing a human genome from roughly $1 billion 23 years ago, when the Human Genome Project was launched, to $3,000 today (and still declining rapidly). The company reported quarterly revenue and earnings growth ahead of Wall Street estimates, driven by strength across its entire product portfolio.We believe these results were driven by both growing end markets and market share gains, which may have accelerated after the company's main competitor announced it was considering selling itself.

From the Baron Funds’ second quarter 2013 commentary.


Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 01, 2013

Illumina, Inc. (ILMN) is a leading provider of genetic analysis tools, including DNA sequencing instruments and consumables. Its shares increased in December 2012 on press reports that Roche Holdings AG, a large Swiss pharmaceutical and diagnostic company, was in discussions to purchase Illumina. In early January, Illumina's shares fell after Roche's CEO was quoted in the press stating that the companies could not reach an agreement on price, and Roche was abandoning its efforts to acquire Illumina. Our investment in Illumina was not predicated on its being acquired, and we remain confident in the company's long-term prospects in the large, fast-growing market for DNA sequencing and genetic analysis.

From Baron Funds’ first quarter 2013 letter.


Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina - Aug 23, 2012

From Baron Funds' second quarter commentary:

We purchased shares of Illumina, Inc. (ILMN), a leading provider of tools and services for advanced genetic analysis. We have been following the company for several years, and we have long admired its business model and management team. During the quarter, we had an opportunity to buy Illumina's shares at a price we believed to be favorable. Roche Holding Ltd., a large Swiss-based pharmaceutical and biotech company, walked away from its hostile bid for Illumina, and Illumina's share price fell.

Illumina is the recognized leader in next generation DNA sequencing, a fast growing market with enormous potential. Until recently, DNA sequencing has been primarily used for research purposes. In the research market, Illumina's technology is the gold standard with approximately 90% of the world's DNA sequencing output currently produced on Illumina's instruments. As a result of rapid advances in technology, the cost of sequencing has declined dramatically over the past decade, and it is expected to fall to $1,000 per human genome in the near future. As the cost of sequencing declines, new applications for DNA sequencing are emerging. For example, sequencing is being used in cancer diagnosis and treatment. In some cases, a physician treating a cancer patient may have the patient's cancer tumor sequenced and may prescribe drugs that target mutations specific to the patient's cancer.

Illumina's sequencing platforms have been adopted by some well-known diagnostic reference labs, and Illumina is partnering with other labs to develop diagnostic kits. Illumina is conducting research and development on proprietary cancer diagnostic panels, initially focused on ovarian, gastric and colorectal cancers. In the future, Illumina management believes that infants will be sequenced at birth and their genetic profile will be used to manage their health throughout their lifetimes. Other market opportunities for Illumina include agricultural biology, veterinary medicine and forensics. Combined, we believe that these new markets have the potential to more than double the size of Illumina's addressable market from $4 billion to over $8 billion.

Although Illumina faces competition, and technology in this field is advancing at a rapid pace, Illumina has a proven track record of innovating, and we believe it will remain a technology leader. Illumina spends a significantly higher percentage of its revenue on research and development than its peers. The management team is highly regarded in the industry and we think has attracted some of the best talent in the field.

Illumina's business comprises an attractive "razor/blade model" in which the company sells instruments and then generates recurring revenue from consumables used with those instruments. The company generates high profit margins, which we think will expand over time as the company's revenue mix shifts to a higher percentage of high-margin consumable revenue generated from its installed instrument base. Illumina has a strong balance sheet, which provides management financial flexibility to re-invest in its business, repurchase shares or acquire new technologies.


Check out Ron Baron latest stock trades

Top Ranked Articles about Illumina Inc

Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose 34% in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. Read more...
Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman) Read more...
Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman) Read more...
Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the quarter, driven by better-than-expected fourth quarter results, strong 2014 financial guidance, and the announcement of multiple new product introductions. The company's most exciting new product is an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe these developments support our view that Illumina has meaningfully distanced itself from its competitors. We believe that nearly all new orders in the sequencing industry are being won by Illumina, affording the company a de facto monopoly in DNA sequencing devices. Further, Illumina retains this remarkable competitive position at a time when demand for next generation DNA sequencing is accelerating rapidly. Read more...
Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN) outperformed during the second quarter. Illumina is the leading provider of next generation DNA sequencing instruments and consumables. In April, the company reported strong first quarter results. Revenues increased 21%, ahead of Wall Street estimates, driven by strength across the entire product portfolio. Earnings also exceeded expectations. We think Illumina's strong first quarter results were driven in part by market share gains, which may have accelerated after the company's main competitor announced it was evaluating strategic alternatives. (Neal Kaufman) Read more...
Baron Funds Comments on Illumina Inc.
Illumina, Inc. (ILMN) is the leading manufacturer of instruments and consumables used by scientists engaged in researching applications for 'next generation' DNA sequencing. Illumina's products have been at the forefront of huge recent advances in technology that have brought the cost of sequencing a human genome from roughly $1 billion 23 years ago, when the Human Genome Project was launched, to $3,000 today (and still declining rapidly). The company reported quarterly revenue and earnings growth ahead of Wall Street estimates, driven by strength across its entire product portfolio.We believe these results were driven by both growing end markets and market share gains, which may have accelerated after the company's main competitor announced it was considering selling itself. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 122.10
ILMN's P/E(ttm) is ranked higher than
67% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.10 vs. ILMN: 122.10 )
ILMN' s 10-Year P/E(ttm) Range
Min: 34.32   Max: 344.72
Current: 122.1

34.32
344.72
P/B 14.30
ILMN's P/B is ranked higher than
52% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. ILMN: 14.30 )
ILMN' s 10-Year P/B Range
Min: 2.33   Max: 16.82
Current: 14.3

2.33
16.82
P/S 16.80
ILMN's P/S is ranked higher than
52% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. ILMN: 16.80 )
ILMN' s 10-Year P/S Range
Min: 3.4   Max: 17.42
Current: 16.8

3.4
17.42
PFCF 100.40
ILMN's PFCF is ranked higher than
75% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 81.48 vs. ILMN: 100.40 )
ILMN' s 10-Year PFCF Range
Min: 13.32   Max: 138.5
Current: 100.4

13.32
138.5
EV-to-EBIT 81.92
ILMN's EV-to-EBIT is ranked higher than
66% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. ILMN: 81.92 )
ILMN' s 10-Year EV-to-EBIT Range
Min: 13.8   Max: 415.7
Current: 81.92

13.8
415.7
PEG 8.00
ILMN's PEG is ranked higher than
79% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 121.00 vs. ILMN: 8.00 )
ILMN' s 10-Year PEG Range
Min: 1.21   Max: 15.23
Current: 8

1.21
15.23
Shiller P/E 218.40
ILMN's Shiller P/E is ranked higher than
79% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ILMN: 218.40 )
ILMN' s 10-Year Shiller P/E Range
Min: 87.03   Max: 2630.5
Current: 218.4

87.03
2630.5
Current Ratio 1.42
ILMN's Current Ratio is ranked higher than
54% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. ILMN: 1.42 )
ILMN' s 10-Year Current Ratio Range
Min: 0.99   Max: 60.21
Current: 1.42

0.99
60.21
Quick Ratio 1.28
ILMN's Quick Ratio is ranked higher than
62% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. ILMN: 1.28 )
ILMN' s 10-Year Quick Ratio Range
Min: 0.87   Max: 60.21
Current: 1.28

0.87
60.21

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 42.30
ILMN's Price/Tangible Book is ranked higher than
57% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.62 vs. ILMN: 42.30 )
ILMN' s 10-Year Price/Tangible Book Range
Min: 1.18   Max: 144.96
Current: 42.3

1.18
144.96
Price/DCF (Projected) 6.30
ILMN's Price/DCF (Projected) is ranked higher than
76% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.59 vs. ILMN: 6.30 )
ILMN' s 10-Year Price/DCF (Projected) Range
Min: 1.53   Max: 72.48
Current: 6.3

1.53
72.48
Price/Median PS Value 2.10
ILMN's Price/Median PS Value is ranked higher than
56% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ILMN: 2.10 )
ILMN' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 94.53
Current: 2.1

0.5
94.53
Price/Peter Lynch Fair Value 8.70
ILMN's Price/Peter Lynch Fair Value is ranked higher than
84% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ILMN: 8.70 )
ILMN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.73   Max: 9.68
Current: 8.7

1.73
9.68
Price/Graham Number 14.30
ILMN's Price/Graham Number is ranked higher than
70% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.49 vs. ILMN: 14.30 )
ILMN' s 10-Year Price/Graham Number Range
Min: 3.3   Max: 12.16
Current: 14.3

3.3
12.16
Earnings Yield (Greenblatt) 1.20
ILMN's Earnings Yield (Greenblatt) is ranked higher than
50% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. ILMN: 1.20 )
ILMN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 7.2
Current: 1.2

0.2
7.2
Forward Rate of Return (Yacktman) 14.81
ILMN's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 257 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. ILMN: 14.81 )
ILMN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4   Max: 37.7
Current: 14.81

-4
37.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:ILU.Germany
Illumina, Inc. was incorporated in California in April 1998 and reincorporated in Delaware in July 2000. The Company is a developer, manufacturer and marketer of integrated systems for the analysis of genetic variation and biological function. Using its proprietary technologies, it provides a line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and it expects to enter the market for molecular diagnostics. The Company's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. It develops and commercializes sequencing technologies used to perform a range of analyses, including de novo sequencing, whole genome re-sequencing, gene expression analysis and small RNA analysis. The Company's product and service offerings also include leading-edge solutions for single-nucleotide polymorphism genotyping, copy number variation, DNA methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. Its tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to determine and analyze the billions of bits of genetic information needed to extract valuable medical information from advances in genomics and proteomics. During the first quarter of 2008, it reorganized its operating structure into two newly-created business segments, the Life Sciences Business Unit and the Diagnostics Business Unit. The Company's Life Sciences Business Unit includes all products and services that are mainly related to the research market, namely the product lines based on its sequencing, BeadArray, and VeraCode technologies, and its Diagnostics Business Unit focuses on the emerging opportunity in molecular diagnostics. It currently sells its products to a number of customers outside the United States, including customers in other areas of North America, Europe, and the Asia-Pacific region. The Company's manufacturing operations require a variety of raw materials, electronic and mechanical components, chemical and biochemical materials, and other supplies. The Company markets and distributes its products directly to customers in North America, Europe, and the Asia-Pacific region. The Company's main competiters are Affymetrix, Inc.; Agilent Technologies, Inc.; Beckman Coulter, Inc.; Complete Genomics, Inc.; General Electric Company; Helicos BioSciences Corporation; Life Technologies Corporation; Luminex Corporation; Pacific Biosciences, Inc.; Roche Diagnostics Corp.; Sequenom, Inc.; and Qiagen N.V. The Company's trademarks are Illumina(r), Array of Arraystm, BeadArraytm, BeadXpress(r), CSPro(r), DASL(r), Genetic Energytm, GoldenGate(r), GoldenGate Indexingtm, GenomeStudio(r), illuminaDxtm, HiSeqtm, Infinium(r), IntelliHyb(r), iSelect(r), Making Sense Out of Life(r), Oligator(r), Sentrix(r), Solexa(r) and VeraCode(r). The
» More Articles for ILMN

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Envision Healthcare Holdings Inc, Google Inc, Illumina Inc. Jul 20 2014 
Baron Funds Comments on Illumina Inc. May 29 2014 
Baron Funds Comments on Illumina Inc. May 21 2014 
Baron Funds Comments on Illumina Inc. May 12 2014 
Baron Funds Comments on Illumina Inc. May 02 2014 
Weekly 52-Week Highs Highlight: SHPG, ILMN, UA, WDAY Feb 23 2014 
Illumina Inc: How Long Can a Miracle Go On? Feb 07 2014 
Baron Funds Comments on Illumina Inc. Aug 08 2013 
Baron Funds Comments on Illumina Inc. Aug 02 2013 
Baron Funds Comments on Illumina Inc. May 01 2013 

More From Our Partners
Earnings Continue Driving Markets Higher Jul 16 2014 - BENZINGA

More From Other Websites
Berry Genomics and Illumina Co-Develop Integrated Next-Generation Sequencing System for Review and... Jul 21 2014
Berry Genomics and Illumina Co-Develop Integrated Next-Generation Sequencing System for Review and... Jul 21 2014
Berry Genomics and Illumina Co-Develop Integrated Next-Generation Sequencing System for Review and... Jul 21 2014
An Unsolicited Comment On Janet Yellen's Biotech Comments Jul 17 2014
Illumina Acquires Myraqa, a Leading IVD and Companion Diagnostic Consulting Firm Jul 16 2014
Illumina acquires Myraqa Jul 16 2014
Illumina Acquires Myraqa, a Leading IVD and Companion Diagnostic Consulting Firm Jul 16 2014
Illumina Names Tina S. Nova as Senior Vice President and General Manager of Oncology Jul 14 2014
Illumina Names Tina S. Nova As Senior Vice Pres And General Manager Of Oncology Jul 14 2014
Illumina Names Tina S. Nova as Senior Vice President and General Manager of Oncology Jul 14 2014
Is NanoString The Next Illumina In Cancer Diagnostics? Jul 14 2014
England Asks Illumina to Map 100,000 Genomes Jul 11 2014
Some Stock Leaders Stay Firm Amid Pullback Jul 10 2014
ILLUMINA INC Files SEC form 8-K, Other Events Jul 09 2014
Illumina to Announce Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 Jul 09 2014
Illumina to Announce Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 Jul 09 2014
Albany Molecular's Oso Buy Seen Boosting Earnings Jul 07 2014
Salix, Jazz Lead As Drugmakers Pace IBD 50 For Week Jul 03 2014
Illumina Expands in Europe on 3 NIPT Deals Jul 01 2014
Growth stocks are doing most bullish thing they can Jul 01 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide